Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 26;57(4):168–171. doi: 10.1007/s13139-023-00804-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), under exclusive licence to Korean Society of Nuclear Medicine 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

PMC Copyright notice

Fig. 1 — A patient with metastatic castration-resistant prostate cancer who progressed on hormonal therapy and was referred for PSMA-RLT. As shown in a maximum intensity projection (MIP) and b sagittal fused PET/CT, ⁶⁸Ga-PSMA PET/CT revealed widespread PSMA-avid bone metastases that were extensive sclerotic in the thoracic spine. ¹⁶¹Tb-PSMA SPECT/CT 24 h after a 5.5 GBq theraputic dose of ¹⁶¹Tb-PSMA RLT demonstrated adequate localization of the ¹⁶¹Tb-PSMA in the metastatic bone deposits, which were extensively expressed in the thoracic spine as demonstrated by sagittal fused SPECT/CT and MIP (c, d)